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Although uncommon, ovarian cancer cells may spread to the rectal lymph nodes. However, few reports have
described how to detect and treat such metastases. We report a case of a 59-year-old woman with mesorectal and
pararectal lymph node metastases in recurrent ovarian carcinoma, detected conclusively using 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography/computed tomography (PET/CT), and treated by low anterior resection
with total mesorectal excision aiming for macroscopic complete resection. The treatment goals for the patient
were gradually changed from curative to palliative chemotherapy; she survived for 45 months without rectal
obstruction after secondary debulking surgery, and was followed up until autopsy. Thus, 18F-FDG PET/CT may be
valuable for detecting rectal lymph node metastasis and can play an essential role in planning treatment for
recurrent ovarian carcinoma.
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Treatment planningBackground
Ovarian carcinoma is the most lethal gynecological ma-
lignancy, mainly because it extensively metastasizes to
various sites through direct invasion, peritoneal dissem-
ination, and lymphatic metastasis [1,2]. Ovarian cancer
cells frequently spread to regional lymph nodes such as
the iliac and para-aortic nodes [3]. Uncommonly, these
cells may also spread to the rectal [4-7], inguinal [8], and
intramammary [9] lymph nodes. However, few reports
have described how to detect and treat such metastases
[10]. Here, we report a case of a 59-year-old woman with
mesorectal and pararectal lymph node metastases in
recurrent ovarian carcinoma, who survived for 45
months after secondary debulking surgery (SDS) and
was followed up until autopsy. We describe the essential
role of 18F-fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography/computed tomography (PET/CT) in
treatment planning.* Correspondence: kumagai.koji@gmail.com
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A 59-year-old para 2 menopausal woman presented with
a 15 cm × 15 cm pelvic tumor. Her mother had a history
of breast cancer. The patient’s serum level of cancer
antigen 125 (CA125) was elevated to 1,615 U/ml
(normal value, <35 U/ml). Laparotomy showed that the
tumor originated in the left ovary and was tightly
attached to both the uterus and the rectum. Ascitic
cytology (<100 ml) results were positive for adenocarcin-
oma. Consequently, the patient underwent total hyster-
ectomy, bilateral salpingo-oophorectomy, and partial
omentectomy (Figure 1). The maximum diameter of the
remaining tumors was less than 1 cm. The operating
time and blood loss were 265 min and 3,360 ml, respect-
ively. The histological diagnosis was stage IIIc ovarian
serous papillary adenocarcinoma, based on the 1994
International Federation of Gynecology and Obstetrics
classification. Subsequently, she received intraperitoneal
chemotherapy followed by adjuvant chemotherapy.
Whenever her serum CA125 level exceeded 100 U/ml,
she received repeated cycles of chemotherapy (Figure 2).
Thirty-four months after surgery, 18F-FDG PET/CT
revealed increased 18F-FDG uptake in two mesorectalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





Figure 1 Formalin-fixed specimens resected at primary surgery. (A) Left ovarian tumor; (B) omentum with metastatic tumor; (C) uterus, right
adnexa, and left fallopian tube; (D) microscopic view of the left ovarian tumor, showing serous papillary adenocarcinoma (hematoxylin and eosin
stain, bar 100 μm).
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node (18 mm) (Figure 3). The results of contrast-
enhanced CT scans obtained 2 weeks earlier were
equivocal for one mesorectal (12 mm) and one
pararectal (18 mm) lymph node (Figure 3: 1A, 1C). The
patient underwent SDS aimed at removing the three
tumors; this surgery involved low anterior resection of
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Figure 2 Changes in cancer antigen 125 (CA125) levels during
treatment. The graph shows the treatments and the number of
chemotherapeutic cycles. We used CPT-11 combined with
cisplatin for three cycles, followed by three cycles of CPT-11
alone; 18F-fluorodeoxyglucose positron emission tomography/
computed tomography was conducted four times (yellow arrows).
CPT-11, camptothecin 11 (also known as irinotecan); DP, docetaxel and
cisplatin; Gem, gemcitabine; IP, intraperitoneal chemotherapy with
cisplatin; PET/CT, positron emission tomography/computed
tomography; TC, paclitaxel and carboplatin.resection of the vaginal cuff. On careful inspection of
the abdominal cavity, no macroscopic peritoneal dissem-
ination was identified. The surgery accomplished macro-
scopic complete resection. Histopathological analysis of
the surgical specimens showed that the tumors were two
mesorectal and one pararectal lymph node metastases;
one paravaginal lymph node (5 mm) had not previously
been detected by 18F-FDG PET/CT (Figure 4). The hist-
ology of all four of the lymph nodes was serous papillary
adenocarcinoma, consistent with ovarian carcinoma
(Figure 4D).
18F-FDG PET/CT was performed at 19 (not shown),
24 (Figure 5), and 36 (not shown) months after SDS, and
18F-FDG uptake in the pelvic lymph nodes was observed.
The patient received palliative chemotherapy until inter-
stitial lung disease occurred. Forty-five months after
SDS, the recurrent tumor invaded the vaginal wall and
the patient died from vaginal hemorrhage, but without
rectal obstruction throughout the clinical course. At aut-
opsy, multiple metastases of the cancer were found, in-
volving the bladder muscle, vaginal wall, pelvic wall, left
kidney, pelvic and para-aortic lymph nodes, and liver
surface (Figure 6).
Our imaging protocol required patients to fast for more
than 5 h before intravenous injection of 18F-FDG (2.6
MBq/kg). After administration of 18F-FDG, an early emis-
sion scan (at 60 min) and delayed emission scan (at 120
min) were obtained in three-dimensional mode from the
orbit to the upper thigh. All scans were performed with a
PET/CT scanner (SET-3000BCT/L; Shimadzu, Kyoto,
Japan), and transmission scans were simultaneously




















Figure 4 Formalin-fixed specimens obtained at the time of the secondary debulking surgery. (A) Intense uptake areas (1 to 3) in the
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) maximum intensity projection image. (B) Specimen from the low anterior
en bloc resection of the rectum; the triangles show the level of peritoneal reflex. (C) Sections 1 and 2 include mesorectal lymph nodes; section V
(vagina) includes the posterior vaginal wall and a paravaginal lymph node; section 3 includes a pararectal lymph node; the arrows indicate loupe

















Figure 3 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) images obtained 34 months
after primary surgery. (A) Axial and (B) coronal PET/CT images show three areas (1 to 3) of increased 18F-FDG uptake adjacent to the rectum.
Maximum standardized uptake values (SUVmax) at 60 and 120 min were (1A) 3.5 and 4.5, (2A) 9.4 and 13.7, and (3A) 6.4 and 7.6, respectively. (C)
Axial contrast-enhanced CT scans were performed 2 weeks earlier, the results of which were equivocal for one mesorectal (1C) and one
pararectal (3C) lymph node. BL, bladder.





















Figure 5 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) images obtained 24 months
after secondary debulking surgery. (A) Axial and (B) coronal PET/CT images show three areas of increased 18F-FDG uptake (1 to 3) in the
pelvic area. Maximum standardized uptake values (SUVmax) at 60 and 120 min were (1A) 6.1 and 7.8, (2A) 3.9 and 6.2, and (3A) 2.7 and 4.1,
respectively. (C) Axial contrast-enhanced CT scans performed 1 week earlier. BL, bladder.
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helical scanner was performed to reconstruct PET/CT
images for visual interpretation and tumor volume
measurements.
Discussion
Here, we report a case of a 59-year-old woman with rec-
tal lymph node metastases in recurrent ovarian carcin-
oma, who survived for 45 months without rectal
obstruction after SDS, whose treatment goal was grad-
ually changed from curative to palliative chemotherapy,
and was followed up until autopsy. Other authors have
reported the role of 18F-FDG PET/CT in the diagnosis
of inguinal lymph node metastases from ovarian carcin-
oma [8,9]. To our knowledge, this is the first report de-
scribing the value of 18F-FDG PET/CT in detecting
rectal lymph node metastasis and in treatment planning
for recurrent ovarian carcinoma.
Rectal lymph node metastases may be more frequent
in ovarian carcinoma than previously believed [4,5].
Gynecologists require anatomical knowledge of lymph
nodes around the rectum, because once ovarian carcin-
oma infiltrates the rectal wall, the pattern of lymphatic
spread may be similar to that of primary rectalcarcinoma [4,5]. However, the location, distribution, and
size of the lymph nodes around the rectum remain
under debate [6,7]. Moreover, there is no consensus on
the nomenclature for lymph nodes around the rectum,
that is, the terms ‘epirectal’, ‘pararectal’, ‘perirectal’, and
‘mesorectal’ are all used in reports by different re-
searchers [3-7]. Further studies are required to establish
more precise topography and a strict nomenclature for
lymph nodes around the rectum.
Visual images are essential for the interpretation of
recurrent ovarian carcinomas, since an elevated CA125
value does not indicate the size or location of the
recurrent tumor. The PET/CT scan has additional
value because it combines functional and metabolic
characteristics with morphological and anatomical im-
ages. Therefore, 18F-FDG PET/CT has high sensitivity in
detection of metastases in lymph nodes larger than 7
mm [11,12], which proved to be the case here: two
mesorectal lymph nodes (12 and 26 mm) and one
pararectal lymph node (18 mm) were detected with 18F-
FDG PET/CT prior to SDS (Figures 3 and 4). Using only
conventional CT, it remains challenging to distinguish
between metastasis and reactive swelling in individual
























Figure 6 Appearance at autopsy. (A) Rear view of the internal organs. (B) Three para-aortic lymph node metastases (L1 to L3). (C) Vaginal wall
involvement. (D) Two metastatic nodules on the liver surface. (E) Left kidney (LK) and bladder (BL) muscle involvement; RK, right kidney. Circles
and arrows indicate loupe/microscopic views of the specimens (hematoxylin and eosin stain, bars 100 μm). AC, ascending colon; AO, aorta; BL,
bladder; DC, descending colon; LK, left kidney; LL, left lung; HLL, hepatic left lobe; RK, right kidney; RL, right lung; TC, transverse colon.
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criminate lymph node metastasis from rectal wall thick-
ness (Figure 3: 3C). In the present case, conventional CT
and PET/CT scans had sensitivities of 25% (excluding in-
determinate findings) and 75%, respectively. Recent
studies have reported that 18F-FDG PET/CT has higher
patient-based sensitivity, specificity, positive predictive
value, and accuracy (53% to 97%, 80% to 97%, 89% to
98%, and 68% to 92%, respectively) than conventional
CT for recurrence of ovarian cancer [11]. Thus, 18F-FDG
PET/CT may be a superior diagnostic tool than conven-
tional CT for detecting rectal lymph node metastasis in
recurrent ovarian carcinoma [10-12].
There has not been much focus on preoperative
planning using 18F-FDG PET/CT in recurrent ovarian
carcinoma. Lenhard et al. [10] reported that recurrent
tumors were completely removed without macroscopic
remnants in 21 of 24 patients in whom the possibility of
complete cytoreduction had been predicted by PET/CT
imaging. Similarly, in the present case, the surgery ac-
complished macroscopic complete resection as predicted
by 18F-FDG PET/CT. Later, 18F-FDG PET/CT identified
multiple metastases in the pelvic lymph nodes (Figure 5);
at that time, we gradually changed the treatment goals
from curative to palliative chemotherapy. The patient
not only survived for a longer time after SDS (45
months) than did other such patients (mean survival
time, 32 months) in previous studies [13], but also expe-
rienced no rectal obstruction, which improved the pa-
tient’s quality of life. Thus, 18F-FDG PET/CT could play
a determinative role in patient management [10].
Dual-point time (DPT) 18F-FDG PET/CT is a semi-
quantitative technique in which analyses are performed
using both early and delayed maximum standardized
uptake values (SUVmax).
18F-FDG is not specific formalignancy; for example, activated inflammatory cells
have increased expression of glucose transporters and
increased 18F-FDG uptake. DPT 18F-FDG PET/CT is
clinically useful, because a lesion is likely to be malig-
nant if SUVmax is increasing over time, whereas it is
likely to be benign if SUVmax is stable or decreasing [14].
Chan et al. [15] reported a significant improvement in
the sensitivity of delayed SUVmax (94% at a mean of 155
min) compared with the sensitivity of early SUVmax
(77% at a mean of 64 min) in detecting 133 malignant
lesions among 53 patients. In the present study, we con-
firmed the lymph nodes as metastatic based on early (at
60 min) and delayed (at 120 min) SUVmax data (Figures 3
and 5). Thus, DTP 18F-FDG PET/CT provides a more
accurate diagnosis than conventional CT for recurrent
ovarian carcinoma.
In 2006, Chi et al. [2,16] established a practical guide-
line for the management of recurrent ovarian carcinoma
based on data from 153 patients treated at their insti-
tute. They proposed that the disease-free interval and
the number of recurrent sites should be used as selec-
tion criteria for whether to offer SDS. 18F-FDG PET/CT
provides more accurate information on the number of
recurrent sites compared with conventional CT [10-12].
Thus, 18F-FDG PET/CT may become an indispensable
imaging modality for determining whether to offer
SDS or avoid unnecessary surgery. Further studies are
needed to determine whether treatment decisions using
18F-FDG PET/CT provide a survival benefit to patients
with recurrent ovarian carcinoma.
Conclusions
18F-FDG PET/CT may be valuable for detecting rectal
lymph node metastasis, and can play an essential role in
planning treatment of recurrent ovarian carcinoma.
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